17,994 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Acquired by Qsemble Capital Management LP

Qsemble Capital Management LP bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the 3rd quarter, Holdings Channel reports. The fund bought 17,994 shares of the company’s stock, valued at approximately $264,000.

Other large investors have also added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. grew its stake in Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares during the period. ORG Wealth Partners LLC acquired a new stake in Elanco Animal Health in the third quarter valued at approximately $29,000. nVerses Capital LLC acquired a new stake in Elanco Animal Health in the second quarter valued at approximately $32,000. ORG Partners LLC acquired a new stake in Elanco Animal Health in the second quarter valued at approximately $31,000. Finally, AM Squared Ltd acquired a new stake in Elanco Animal Health in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Barclays raised their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health has an average rating of “Hold” and a consensus price target of $17.14.

Elanco Animal Health Price Performance

ELAN stock opened at $13.13 on Thursday. Elanco Animal Health Incorporated has a twelve month low of $11.40 and a twelve month high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average is $13.66 and its 200-day moving average is $14.69. The firm has a market capitalization of $6.49 billion, a PE ratio of 33.10, a P/E/G ratio of 1.40 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. Sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.